Methods of treatment using stem cell mobilizers

Abstract

The present invention relates to the field of stem cells. In one aspect, the present invention provides methods of treating a subject with acute liver injury comprising administering to the subject a therapeutically effective amount of at least one stem cell mobilizer. In particular embodiments, the subject is treated with plerixafor and G-CSF

1 . A method for treating a subject with acute liver injury comprising administering to the subject a therapeutically effective amount of at least one stem cell mobilizer. 
     
     
         2 . The method of  claim 1 , wherein the at least one stem cell mobilizer is selected from the group consisting of plerixafor, AMD3465, NIBR1816, TG-0054, G-CSF, GM-CSF, SDF-1, and SCF. 
     
     
         3 . The method of  claim 2 , wherein the subject is treated with plerixafor and G-CSF. 
     
     
         4 . The method of  claim 3 , wherein plerixafor is administered in a range of about 200 μg to about 3 mg per kg of body weight. 
     
     
         5 . The method of  claim 4 , wherein plerixafor is administered in a dose of about 2 mg/kg of body weight. 
     
     
         6 . The method of  claim 3 , wherein G-CSF is administered in a range of about 10 μg to about 1 mg/kg of body weight. 
     
     
         7 . The method of  claim 6 , wherein G-CSF is administered in a dose of about 300 μg/kg of body weight. 
     
     
         8 . The method of  claim 1 , wherein the at least one stem cell mobilizer is a CXCR4 antagonist. 
     
     
         9 . The method of  claim 8 , wherein the CXCR4 antagonist is selected from the group consisting of plerixafor, AMD3465, NIBR1816, and TG-0054. 
     
     
         10 . The method of  claim 1 , wherein the acute liver injury comprises acute liver failure. 
     
     
         11 . The method of  claim 1 , wherein the acute liver injury comprises post-surgical resection. 
     
     
         12 . A method for treating a subject with acute liver failure comprising administering to the subject a therapeutically effective amount of at least one stem cell mobilizer. 
     
     
         13 . The method of  claim 12 , wherein the at least one stem cell mobilizer is selected from the group consisting of plerixafor, AMD3465, NIBR1816, TG-0054, G-CSF, GM-CSF, SDF-1, and SCF. 
     
     
         14 . The method of  claim 13 , wherein the subject is treated with plerixafor and G-CSF. 
     
     
         15 . The method of  claim 14 , wherein plerixafor is administered in a range of about 200 μg to about 3 mg per kg of body weight. 
     
     
         16 . The method of  claim 15 , wherein plerixafor is administered in a dose of about 2 mg/kg of body weight. 
     
     
         17 . The method of  claim 14 , wherein G-CSF is administered in a range of about 10 μg to about 1 mg/kg of body weight. 
     
     
         18 . The method of  claim 17 , wherein G-CSF is administered in a dose of about 300 μg/kg of body weight. 
     
     
         19 . The method of  claim 12 , wherein the at least one stem cell mobilizer is a CXCR4 antagonist. 
     
     
         20 . The method of  claim 19 , wherein the CXCR4 antagonist is selected from the group consisting of plerixafor, AMD3465, NIBR1816, and TG-0054. 
     
     
         21 . A method for treating a subject with acute liver failure comprising administering to the subject a therapeutically effective amount of plerixafor and a therapeutically effective amount of G-CSF. 
     
     
         22 . A method for treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of at least one stem cell mobilizer. 
     
     
         23 . The method of  claim 22 , wherein the organ is selected from the group consisting of liver, kidney, skin, heart, lung, intestine, and pancreas. 
     
     
         24 . A method for treating a composite tissue transplant recipient comprising administering to the recipient a therapeutically effective amount of at least one stem cell mobilizer. 
     
     
         25 . A method for treating a subject diagnosed with ischemic injury comprising administering to the recipient a therapeutically effective amount of at least one stem cell mobilizer. 
     
     
         26 . The method of  claim 22 , wherein the at least one stem cell mobilizer is selected from the group consisting of plerixafor, AMD3465, NIBR1816, TG-0054, G-CSF, GM-CSF, SDF-1, and SCF. 
     
     
         27 . The method of  claim 26 , wherein the subject is treated with plerixafor and G-CSF. 
     
     
         28 . The method of  claim 27 , wherein plerixafor is administered in a range of about 200 μg to about 3 mg per kg of body weight. 
     
     
         29 . The method of  claim 28 , wherein plerixafor is administered in a dose of about 2 mg/kg of body weight. 
     
     
         30 . The method of  claim 27 , wherein G-CSF is administered in a range of about 10 μg to about 1 mg/kg of body weight. 
     
     
         31 . The method of  claim 30 , wherein G-CSF is administered in a dose of about 300 μg/kg of body weight. 
     
     
         32 . The method of  claim 22 , wherein the at least one stem cell mobilizer is a CXCR4 antagonist. 
     
     
         33 . The method of  claim 32 , wherein the CXCR4 antagonist is selected from the group consisting of plerixafor, AMD3465, NIBR1816, and TG-0054.